Medications With Minimal Effects on Plasma Aldosterone Levels That Can Control Hypertension During Case Finding and Confirmatory Testing for PA
| Drug . | Class . | Usual Dose . | Comments . |
|---|---|---|---|
| Verapamil slow-release | Non-dihydropyridine slow-release antagonist calcium channel | 90–120 mg twice daily | Use singly or in combination with the other agents listed in this table |
| Hydralazine | Vasodilator | 10–12.5 mg twice daily, increasing as required | Commence verapamil slow-release first to prevent reflex tachycardia. Commencement at low doses reduces risk of side effects (including headaches, flushing, and palpitations) |
| Prazosin hydrochloride | α-Adrenergic blocker | 0.5–1 mg two or three times daily, increasing as required | Monitor for postural hypotension |
| Doxazosin mesylate | α-Adrenergic blocker | 1–2 mg once daily, increasing as required | Monitor for postural hypotension |
| Terazosin hydrochloride | α-Adrenergic blocker | 1–2 mg once daily, increasing as required | Monitor for postural hypotension |
| Drug . | Class . | Usual Dose . | Comments . |
|---|---|---|---|
| Verapamil slow-release | Non-dihydropyridine slow-release antagonist calcium channel | 90–120 mg twice daily | Use singly or in combination with the other agents listed in this table |
| Hydralazine | Vasodilator | 10–12.5 mg twice daily, increasing as required | Commence verapamil slow-release first to prevent reflex tachycardia. Commencement at low doses reduces risk of side effects (including headaches, flushing, and palpitations) |
| Prazosin hydrochloride | α-Adrenergic blocker | 0.5–1 mg two or three times daily, increasing as required | Monitor for postural hypotension |
| Doxazosin mesylate | α-Adrenergic blocker | 1–2 mg once daily, increasing as required | Monitor for postural hypotension |
| Terazosin hydrochloride | α-Adrenergic blocker | 1–2 mg once daily, increasing as required | Monitor for postural hypotension |
[Adapted from J. W. Funder et al: Case detection, diagnosis, and treatment of patients with primary aldosteronism: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2008;93:3266–3281 (3), with permission. © Endocrine Society.]
Medications With Minimal Effects on Plasma Aldosterone Levels That Can Control Hypertension During Case Finding and Confirmatory Testing for PA
| Drug . | Class . | Usual Dose . | Comments . |
|---|---|---|---|
| Verapamil slow-release | Non-dihydropyridine slow-release antagonist calcium channel | 90–120 mg twice daily | Use singly or in combination with the other agents listed in this table |
| Hydralazine | Vasodilator | 10–12.5 mg twice daily, increasing as required | Commence verapamil slow-release first to prevent reflex tachycardia. Commencement at low doses reduces risk of side effects (including headaches, flushing, and palpitations) |
| Prazosin hydrochloride | α-Adrenergic blocker | 0.5–1 mg two or three times daily, increasing as required | Monitor for postural hypotension |
| Doxazosin mesylate | α-Adrenergic blocker | 1–2 mg once daily, increasing as required | Monitor for postural hypotension |
| Terazosin hydrochloride | α-Adrenergic blocker | 1–2 mg once daily, increasing as required | Monitor for postural hypotension |
| Drug . | Class . | Usual Dose . | Comments . |
|---|---|---|---|
| Verapamil slow-release | Non-dihydropyridine slow-release antagonist calcium channel | 90–120 mg twice daily | Use singly or in combination with the other agents listed in this table |
| Hydralazine | Vasodilator | 10–12.5 mg twice daily, increasing as required | Commence verapamil slow-release first to prevent reflex tachycardia. Commencement at low doses reduces risk of side effects (including headaches, flushing, and palpitations) |
| Prazosin hydrochloride | α-Adrenergic blocker | 0.5–1 mg two or three times daily, increasing as required | Monitor for postural hypotension |
| Doxazosin mesylate | α-Adrenergic blocker | 1–2 mg once daily, increasing as required | Monitor for postural hypotension |
| Terazosin hydrochloride | α-Adrenergic blocker | 1–2 mg once daily, increasing as required | Monitor for postural hypotension |
[Adapted from J. W. Funder et al: Case detection, diagnosis, and treatment of patients with primary aldosteronism: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2008;93:3266–3281 (3), with permission. © Endocrine Society.]
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
